Literature DB >> 32359480

Considering the Immune System during Fecal Microbiota Transplantation for Clostridioides difficile Infection.

Alyse L Frisbee1, William A Petri2.   

Abstract

Our understanding and utilization of fecal microbiota transplantation (FMT) has jump-started over the past two decades. Recent technological advancements in sequencing and metabolomics have allowed for better characterization of our intestinal microbial counterparts, triggering a surge of excitement in the fields of mucosal immunology and microbiology. This excitement is well founded, as demonstrated by 90% relapse-free cure rates in FMT treatment for recurrent Clostridioides difficile infections. Growing evidence suggests that in addition to bacterial factors, the host immune response during C. difficile infection greatly influences disease severity. In this review, we discuss recent advancements in understanding the interplay between immune cells and the microbiota and how they may relate to recovery from C. difficile through FMT therapy.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  fecal microbiota transplantation; gut microbiota; immunity; infection

Year:  2020        PMID: 32359480      PMCID: PMC7198612          DOI: 10.1016/j.molmed.2020.01.009

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  96 in total

Review 1.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

2.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

Review 3.  Intestinal epithelial cells: regulators of barrier function and immune homeostasis.

Authors:  Lance W Peterson; David Artis
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

4.  Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.

Authors:  Jim G Castellanos; Viola Woo; Monica Viladomiu; Gregory Putzel; Svetlana Lima; Gretchen E Diehl; Andrew R Marderstein; Jorge Gandara; Alexendar R Perez; David R Withers; Stephan R Targan; David Q Shih; Ellen J Scherl; Randy S Longman
Journal:  Immunity       Date:  2018-12-11       Impact factor: 31.745

5.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; R N Greenberg; M Rubin; R Fekety; M E Mulligan; R J Garcia; S Brandmarker; K Bowen; D Borjal; G W Elmer
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

6.  Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits.

Authors:  Katharina Brandl; George Plitas; Coralia N Mihu; Carles Ubeda; Ting Jia; Martin Fleisher; Bernd Schnabl; Ronald P DeMatteo; Eric G Pamer
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

7.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.

Authors:  Koji Atarashi; Takeshi Tanoue; Kenshiro Oshima; Wataru Suda; Yuji Nagano; Hiroyoshi Nishikawa; Shinji Fukuda; Takuro Saito; Seiko Narushima; Koji Hase; Sangwan Kim; Joëlle V Fritz; Paul Wilmes; Satoshi Ueha; Kouji Matsushima; Hiroshi Ohno; Bernat Olle; Shimon Sakaguchi; Tadatsugu Taniguchi; Hidetoshi Morita; Masahira Hattori; Kenya Honda
Journal:  Nature       Date:  2013-07-10       Impact factor: 49.962

8.  Fecal Microbiota Transplantation Ameliorates Experimentally Induced Colitis in Mice by Upregulating AhR.

Authors:  Yan-Ling Wei; Yu-Qin Chen; Hao Gong; Ning Li; Kang-Qi Wu; Wang Hu; Bin Wang; Kai-Jun Liu; Liang-Zhi Wen; Xiao Xiao; Dong-Feng Chen
Journal:  Front Microbiol       Date:  2018-08-24       Impact factor: 5.640

9.  Microbiota-accessible carbohydrates suppress Clostridium difficile infection in a murine model.

Authors:  Andrew J Hryckowian; William Van Treuren; Samuel A Smits; Nicole M Davis; Jackson O Gardner; Donna M Bouley; Justin L Sonnenburg
Journal:  Nat Microbiol       Date:  2018-04-23       Impact factor: 17.745

10.  Type 2 innate lymphoid cells control eosinophil homeostasis.

Authors:  Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

View more
  9 in total

Review 1.  Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.

Authors:  Larry K Kociolek; Joseph P Zackular; Tor Savidge
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

2.  Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Associates With Functional Alterations in Circulating microRNAs.

Authors:  Tanya M Monaghan; Anna M Seekatz; Nicholas O Markham; Tung On Yau; Maria Hatziapostolou; Tahseen Jilani; Niki Christodoulou; Brandi Roach; Eleni Birli; Odette Pomenya; Thomas Louie; D Borden Lacy; Peter Kim; Christine Lee; Dina Kao; Christos Polytarchou
Journal:  Gastroenterology       Date:  2021-04-09       Impact factor: 33.883

3.  Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.

Authors:  N Jan; R A Hays; D N Oakland; P Kumar; G Ramakrishnan; B W Behm; W A Petri; C Marie
Journal:  mSphere       Date:  2021-10-27       Impact factor: 4.389

Review 4.  Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection.

Authors:  Lucas F Soveral; Gabriela G Korczaguin; Pedro S Schmidt; Isabel S Nunes; Camilo Fernandes; Carlos R Zárate-Bladés
Journal:  World J Gastroenterol       Date:  2022-09-07       Impact factor: 5.374

Review 5.  Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease.

Authors:  Jonathan P Segal; Benjamin H Mullish; Mohammed N Quraishi; Tariq Iqbal; Julian R Marchesi; Harry Sokol
Journal:  Therap Adv Gastroenterol       Date:  2020-09-03       Impact factor: 4.409

Review 6.  Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies.

Authors:  Jia-Wei He; Xu-Jie Zhou; Ji-Cheng Lv; Hong Zhang
Journal:  Theranostics       Date:  2020-09-15       Impact factor: 11.556

7.  Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection.

Authors:  Kelsey E Huus; Marcin Frankowski; Maja Pučić-Baković; Frano Vučković; Gordan Lauc; Benjamin H Mullish; Julian R Marchesi; Tanya M Monaghan; Dina Kao; B Brett Finlay
Journal:  Gut Microbes       Date:  2021 Jan-Dec

8.  Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI?

Authors:  Daniel Popa; Bogdan Neamtu; Manuela Mihalache; Adrian Boicean; Adela Banciu; Daniel Dumitru Banciu; Doru Florian Cornel Moga; Victoria Birlutiu
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

9.  Different Alterations in Gut Microbiota between Bifidobacterium longum and Fecal Microbiota Transplantation Treatments in Propionic Acid Rat Model of Autism.

Authors:  Turki S Abujamel; Norah M Al-Otaibi; Sameera Abuaish; Rahaf H AlHarbi; Mushref B Assas; Saleha Ahmad Alzahrani; Sohailah Masoud Alotaibi; Afaf El-Ansary; Kawther Aabed
Journal:  Nutrients       Date:  2022-01-30       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.